MXPA04004826A - Antagonista del receptor de quimioquinas y metodos para su uso. - Google Patents
Antagonista del receptor de quimioquinas y metodos para su uso.Info
- Publication number
- MXPA04004826A MXPA04004826A MXPA04004826A MXPA04004826A MXPA04004826A MX PA04004826 A MXPA04004826 A MX PA04004826A MX PA04004826 A MXPA04004826 A MX PA04004826A MX PA04004826 A MXPA04004826 A MX PA04004826A MX PA04004826 A MXPA04004826 A MX PA04004826A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- receptor antagonists
- chemokine receptor
- activation
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Se describen compuestos novedosos y los metodos para tratar una enfermedad asociada con el reclutamiento y/o la activacion de leucocitos aberrante. El metodo comprende administrar a un sujeto que lo necesite una cantidad eficaz de un compuesto representado por: o una sal fisiologicamente aceptable del mismo.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/148,823 US6613905B1 (en) | 1998-01-21 | 1998-09-04 | Chemokine receptor antagonists and methods of use therefor |
US09/235,102 US6329385B1 (en) | 1998-01-21 | 1999-01-21 | Chemokine receptor antagonists and methods of use therefor |
US09/362,837 US6509346B2 (en) | 1998-01-21 | 1999-07-28 | Chemokine receptor antagonists and methods of use therefor |
US62788600A | 2000-07-28 | 2000-07-28 | |
US09/989,086 US20020169155A1 (en) | 1998-09-04 | 2001-11-21 | Chemokine receptor anagonists and methods of use therefor |
PCT/US2002/036953 WO2003045942A2 (en) | 1998-09-04 | 2002-11-13 | Chemokine receptor antagonists and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04004826A true MXPA04004826A (es) | 2004-08-11 |
Family
ID=46204639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04004826A MXPA04004826A (es) | 1998-09-04 | 2002-11-13 | Antagonista del receptor de quimioquinas y metodos para su uso. |
Country Status (4)
Country | Link |
---|---|
EA (1) | EA008060B1 (es) |
HU (1) | HU228314B1 (es) |
MX (1) | MXPA04004826A (es) |
WO (1) | WO2003045942A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
TWI291467B (en) | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
NZ550665A (en) | 2004-04-09 | 2010-05-28 | Chugai Pharmaceutical Co Ltd | Novel water-soluble prodrugs of camptothecin derivatives |
WO2006066200A2 (en) * | 2004-12-17 | 2006-06-22 | Millennium Pharmaceuticals, Inc. | Solid forms of a chemokine receptor antagonist and methods of use thereof |
JP2009518313A (ja) * | 2005-11-30 | 2009-05-07 | スミスクライン・ビーチャム・コーポレイション | ピロリジンアニリン |
JP2007297306A (ja) * | 2006-04-28 | 2007-11-15 | Kaneka Corp | 光学活性3−(1−ピロリジニル)ピロリジンの製造法 |
WO2009071509A1 (en) | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
WO2009104557A1 (ja) * | 2008-02-21 | 2009-08-27 | 株式会社カネカ | N-(3-ピロリジニル)グリシン誘導体の製造法 |
US9145383B2 (en) | 2012-08-10 | 2015-09-29 | Hallstar Innovations Corp. | Compositions, apparatus, systems, and methods for resolving electronic excited states |
WO2014025370A1 (en) | 2012-08-10 | 2014-02-13 | Hallstar Innovations Corp. | Tricyclic energy quencher compounds for reducing singlet oxygen generation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031469A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
US6509346B2 (en) * | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
DE69928226T8 (de) * | 1998-01-21 | 2006-10-19 | Millennium Pharmaceuticals, Inc., Cambridge | Chemokin rezeptor antagonisten und verwendung |
-
2002
- 2002-11-13 HU HU0500079A patent/HU228314B1/hu not_active IP Right Cessation
- 2002-11-13 EA EA200400692A patent/EA008060B1/ru not_active IP Right Cessation
- 2002-11-13 WO PCT/US2002/036953 patent/WO2003045942A2/en active Application Filing
- 2002-11-13 MX MXPA04004826A patent/MXPA04004826A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EA200400692A1 (ru) | 2004-12-30 |
HU228314B1 (hu) | 2013-03-28 |
HUP0500079A3 (en) | 2009-03-30 |
HUP0500079A2 (hu) | 2005-04-28 |
WO2003045942A3 (en) | 2003-09-12 |
WO2003045942A2 (en) | 2003-06-05 |
EA008060B1 (ru) | 2007-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1044333A1 (zh) | 趨化因子受體拮抗劑及其使用方法 | |
ATE309249T1 (de) | Chemokin rezeptor antagonisten und verwndung | |
EA199700117A1 (ru) | Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
BG103740A (en) | Phytostyrene composition for the prevention of the alzheimer's disease | |
BG106104A (en) | Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation | |
EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
MXPA04004826A (es) | Antagonista del receptor de quimioquinas y metodos para su uso. | |
TR200103680T2 (tr) | IL-8 reseptör antagonistleri. | |
CA2326339A1 (en) | Use of dexmedetomidine for icu sedation | |
GEP20043267B (en) | Adenosine Receptor Antagonists, Methods of Making and Using the Same | |
ATE174508T1 (de) | Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase | |
EA200000693A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
WO2001009119A3 (en) | Chemokine receptor antagonists | |
SG165152A1 (en) | Chemokine receptor antagonists and methods of use thereof | |
AU655958B2 (en) | Use of quisqualate-receptor antagonists for treating Parkinson's disease | |
IL118833A0 (en) | The use of sertraline to treat post myocardial infarction patients | |
GR1002910B (el) | Δερματικο διαλυμα για απ'ευθειας αποθεση για αντιπαρασιτικη χρηση στα βοοειδη και προβατα | |
ES2074946A1 (es) | Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. | |
GB9420747D0 (en) | 1,5 benzodiazepine derivatives | |
WO2001009094A3 (en) | Chemokine receptor antagonists and methods of use therefor | |
PT2266558T (pt) | Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano | |
MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" | |
MX9602793A (es) | Uso de sertralina para tratar pacientes despues de un infarto de miocardio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |